Fennec Pharmaceuticals (TSE:FRX) Share Price Crosses Above 50-Day Moving Average of $7.77

Fennec Pharmaceuticals Inc. (TSE:FRXGet Rating) shares crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$7.77 and traded as high as C$8.59. Fennec Pharmaceuticals shares last traded at C$8.59, with a volume of 100 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Wedbush restated an “outperform” rating on shares of Fennec Pharmaceuticals in a research report on Thursday, May 12th.

Fennec Pharmaceuticals Stock Down 1.2 %

The business has a 50-day simple moving average of C$7.77 and a two-hundred day simple moving average of C$7.20. The stock has a market capitalization of C$223.68 million and a P/E ratio of -10.50. The company has a quick ratio of 8.55, a current ratio of 8.96 and a debt-to-equity ratio of 39.84.

Fennec Pharmaceuticals (TSE:FRXGet Rating) last announced its quarterly earnings results on Thursday, May 12th. The biopharmaceutical company reported C($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of C($0.17) by C($0.01).

Fennec Pharmaceuticals Company Profile

(Get Rating)

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate that has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

Recommended Stories

Want More Great Investing Ideas?

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.